Antibiotic resistance is associated with longer bacteremic episodes and worse outcome in febrile neutropenic children with cancer

Pediatric Blood and Cancer

Volumn 57, Issue 2, 2011, Pages 283-288

  El Mahallawy, Hadir A ^a   El Wakil, Mohamed ^b,c   Moneer, Manar M ^c   Shalaby, Lobna ^c  

^a CAIRO UNIVERSITY   (Egypt)

^b BENI SUEF UNIVERSITY   (Egypt)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

Antibiotic resistance; Bacteremia; Febrile neutropenia; Multiresistant organism (MRO); Pediatric oncology

Indexed keywords

ANTINEOPLASTIC AGENT;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTEREMIA; BACTERIUM ISOLATION; BLOOD CULTURE; CANCER CHEMOTHERAPY; CANCER PATIENT; CHILD; CHILDHOOD CANCER; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DRUG USE; FEBRILE NEUTROPENIA; FEMALE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MULTIDRUG RESISTANCE; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCHOOL CHILD; SOLID TUMOR;

ADOLESCENT; BACTEREMIA; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EGYPT; FEMALE; HUMANS; INFANT; LOGISTIC MODELS; MALE; MULTIVARIATE ANALYSIS; NEOPLASMS; NEUTROPENIA; PROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 79958854499     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22926     Document Type: Article

References (19)

1. Basu S, Fernandez I, Fisher S, et al. Length of stay and mortality associated with febrile neutropenia among children with cancer. J Clin Oncol 2005;23:7958-7966.
2. Mendes AV, Sapolnik R, Mendonca N. New guidelines for the clinical management of febrile neutropenia and sepsis in pediatric oncology patients. J Pediatr (RioJ) 2007;83:S54-S63.
3. Roberts R, Hota B, Ahmad I, et al. Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: Implications for antibiotic stewardship. Clin Infect Dis 2009;49:1175-1184.
4. Howard DH, Scott RD, Packard R, et al. The global impact of drug resistance. Clin Infect Dis 2003;36:S4-S10.
5. Bailey LC, Reilly AF, Rheingold SR. Infections in pediatric patients with hematologic malignancies. Semin Hematol 2009;46:313-324.
6. Cattaneo C, Quaresmini G, Casari S, et al. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant Escherichia coli among patients with hematological malignancies: Results of a prospective study on 823 patients at a single institution. J Antimicrob Chemother 2008;61:721-728.
7. Castagnola E, Haupt R, Micozzi A, et al. Differences in the proportions of fluoroquinolone-resistant Gram negative bacteria isolated from bacteraemic children with cancer in two Italian centers. Clin Microbiol Infect 2005;11:505-507.
8. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved Standard, 7th edition, CLSI document M7-A7. Wayne, PA: CLSI; 2006.
9. Adams-Haduch JM, Paterson DL, Sidjabat HE, et al. Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. Antimicrob Agents Chemother 2008;52:3837-3843.
10. Ascioglu S, Rex JH, de Pauw W, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: An International Consensus. Clin Infect Dis 2002;34:7-14.
11. Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 2004;39:S25-S31.
12. Khan MA, Siddiqui BK, Shamim A, et al. Emerging bacterial resistance patterns in febrile neutropenic patients: Experience at a tertiary care hospital in Pakistan. J Pak Med Assoc 2004;54:357-360.
13. Velasco E, Byington R, Martins CS, et al. Bloodstream infection surveillance in a cancer centre: A preospective look at clinical microbiology aspects. Clin Microbiol Infect 2004;10:542-549.
14. Cheguirian ML, Carvajal LR, Ledesma EM, et al. Prevalence and antimicrobial susceptibility patterns of microorganisms causing bacteremia and fungemia in pediatric oncology patients. Rev Argent Microbiol 2008;40:111-115.
15. El-Mahallawy H, Sidhom I, El-Din NH, et al. Clinical and microbiologic determinants of serious bloodstream infections in Egyptian pediatric cancer patients: A one-year study. Int J Infect Dis 2005;9:43-51.
16. Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: Multidrug-resistant Acinetobacter baumanii. Nat Rev Microbiol 2007;5:939-951.
17. Chen WH, Luh KT. Relationship between antimicrobial use and antimicrobial resistance in Gram-negative bacteria causing nosocomial infections from 1991-2003 at a university hospital in Taiwan. Int J Antimicrob Agents 2005;26:463-472.
18. Paul M, Grozinsky S, Soares-Weiser K, et al. Beta lactam antibiotic monotherapy versus beta lactam aminoglycoside antibiotic combination therapy for sepsis. The Cochrane Library, John Wiley & Sons 2009, issue 4: 1-142.
19. Pong A, Bradely J. Clinical challenges of nosocomial infections caused by antibiotic-resistant pathogens in pediatrics. Semin Pediatr Infect Dis 2004;15:21-29.